AVAVA MIRIA
Novel Non-Ablative · 1550nm focal-point intradermal fractional
AVAVA MIRIA pricing is not published by the manufacturer, and we have not yet verified a US market range. AVAVA MIRIA holds FDA 510(k) clearance for its marketed indication. Figures are market estimates verified August 6, 2026.
What it's actually cleared for: Focused-beam dermal skin renewal, acne scars, benign pigmented lesions
Last verified: August 6, 2026 · How we verify
New: —|Used: —market estimate, no email required
| Manufacturer | AVAVA |
|---|---|
| Company | Not published |
| Category | Resurfacing, Tattoo & Vascular |
| Technology | 1550nm focal-point intradermal fractional |
| FDA status | FDA Cleared |
| New price range | Not published |
| Used price range | Not published |
| Consumables | Not published |
| Launch year | 2023 |
| Last verified | August 6, 2026 |
Overview
Conical beam tech marketed for all skin tones
FDA & regulatory status
What it's actually cleared for:
Focused-beam dermal skin renewal, acne scars, benign pigmented lesions
510(k) numbers
K250402
Regulatory data is compiled from public FDA 510(k) records and may lag recent clearances. Always confirm status with the manufacturer before purchase.
Treatment economics
Economics data for this platform hasn't been published yet.
Chains using this device
No confirmed chain deployments recorded yet.
Owner reviews
Write a reviewNo verified reviews yet — be the first. Founding reviewers get a thank-you gift card for an honest review, positive or negative. How verification works.
Alternatives
History
Every tracked change to pricing, lifecycle status, FDA data and warranty terms — newest first.
August 1, 2026
Record created
Added to The Aesthetic Index — August 2026
Source: The Aesthetic Index editorial
Get the full State of Aesthetic Devices 2026 report
The first full census of the US aesthetic device market — preview it free.